OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholde... (er relations please call 954-357-0614. ....)

HOME >> MEDICINE >> TECHNOLOGY

OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010

Date:11/5/2009

er relations please call 954-357-0614.

About Virtual Health Technologies, Inc.

VHGI is a diverse company with assets and interests focusing on opportunities within the Healthcare Technology Industry and Precious Metals / Energy Resources Markets. VHGI has recently initiated steps to leverage the company's operating history and corporate resources within the Gold Mining, Precious Metals and Energy Resources Markets. Although Gold is selling at 25 year high prices and Oil & Gas continue to be trading at significant premiums, global economic events have created significant opportunities within these markets. VHGI intends to pursue these opportunities through Lease-Purchase opportunities, Acquisitions and Joint Ventures for the goal of enhanced shareholder value.

Virtual Health Technologies, Inc. cautions investors that none of the information concerning the valuations of mineral deposits or other data reported above have been verified by outside geologists or other verifiable sources.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is leveraging its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also believes it is positioned to develop its technology in Cancer Treatment. For more information on the Company please visit www.woundmanagementtechnologies.com or call our shareholder information department at 859-514-6982.

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the c
'/>"/>

SOURCE VirtualHealth Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:

(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...

(Date:6/19/2013)... 19, 2013 Life Technologies Corporation ... agreement granting Suzhou Ribo Life Sciences (Ribo) the ... in China using Life,s ... siRNA molecules in combination with Invivofectamine® Rx to ... diseases with high unmet medical need in the ...

(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...

Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2 NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3 NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4 NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5 NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6 Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2 Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3 Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4 Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2

[0] NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease [0] Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China [0] Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt

... Gene Expression in Female and Male Patients Presented at ASCO ... (Nasdaq: GHDX ) today announced results from a ... type DX(R) breast cancer test in a large number ... guide treatment with chemotherapy. The results, which will be presented ...

... ET Today CORAL GABLES, Fla., May 29 ... today announced top-line results from its U.S. Phase II ... from the trial showed that CPP-109 did not demonstrate ... significantly larger proportion of CPP-109-treated subjects than placebo-treated subjects ...

Cached Medicine Technology:Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women 2 Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women 3 Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women 4 Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women 5 Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 2 Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 3 Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 4

Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Alternatives, ... permits some patients to quit using drugs while allowing ... Adi Jaffe, the founders of Alternatives, believe that abstinence-only ... before they enter treatment and that this approach hurts ... million people in the United States need treatment for ...

(Date:6/19/2013)... St. Louis, MO (PRWEB) June 19, 2013 ... solutions organization, partnered with ARAMARK Healthcare Technologies to ... equipment management plan with savings of more than ... repair and maintenance service expenditures. , “Driving economies ... the top medical equipment management challenges facing multi-site ...

(Date:6/19/2013)... a world-leading provider of scientific, technical and medical ... of the National Osteoporosis Guideline Group (NOGG) Update ... postmenopausal women and older men in the journal ... Maturitas , the original guidelines have been ... an additional focus on the management of glucocorticoid-induced ...

(Date:6/19/2013)... Mass. (PRWEB) June 19, 2013 ... security solutions, today announced that Imprivata OneSign ® ... KLAS® 2013 Mid-Term Performance Review: Software & Services report ... KLAS laud Imprivata on the superior performance of its ... support, and they indicate that Imprivata is integral to ...

(Date:6/19/2013)... According to Transparency Market Research “Endoscopy devices Market ... Forecast, 2011 – 2017,” the global endoscopy devices market ... and is expected to reach USD 10.8 billion by ... to 2017. Flexible endoscopes formed the largest category in ... for the year 2011. , Related Report : Medical ...

Breaking Medicine News(10 mins):Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2 Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3 Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2 Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2 Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3 Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2 Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3

[0] Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment [0] Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program [0] Maturitas publishes 2013 update on diagnosis and management of osteoporosis [0] Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review [0] Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research

... NEW YORK, Aug. 7 Duane Reade Holdings, Inc. ... previously announced offers by its wholly-owned subsidiaries, Duane Reade Inc. ... (i) any and all of the Issuers, $210,000,000 outstanding aggregate ... 2010 (the "Floating Rate Notes") (the "FRN Offer") and (ii) ...

... , NEW YORK, Aug. 7 WebMD ... HLTH ) today announced that executives of WebMD are scheduled to ... August 12, 2009 at 1:00 p.m. ET. , , ... to a live audio broadcast of the presentation over the Internet. ...

... The poll results come on the heels of the federal government,s new H1N1 ... A poll conducted by the American Red Cross shows that while a majority ... a third of parents (39%) have received no flu information from their children,s ... http://www.newscom.c o m/cgi-bin/prnh/20090108/RedCrossLOGO ) , , ...

... government to preserve study options , FRIDAY, Aug. 7 (HealthDay ... lines are routinely used by researchers in the United States, says ... known as H1 and H9, accounted for 941 of 1,217 requests, ... stem cell lines housed at the two largest stem cell banks ...

... INDIANAPOLIS Poor communication of the outcomes of medical ... a patient,s hospital discharge is common and can lead ... A new study by researchers from the Regenstrief ... found that hospital discharge summaries are grossly inadequate at ...

... , , WASHINGTON, Aug. 7 "The differences between ... policy experts," say former Chief of Staff to the House Aging Committee ... Americans, lives." , , In an op-ed column in ... Osserman contend, "With no public option, the Senate Finance bill, developed by ...

Cached Medicine News:Health News:Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures 2 Health News:Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures 3 Health News:Red Cross Poll Shows Parents Still Lack H1N1 Information From Schools 2 Health News:U.S. Stem Cell Research Seems to Focus on Two Lines 2 Health News:Fumbled handoffs can lead to medical errors 2 Health News:Ex-House Aging Committee Chief of Staff Bob Weiner Warns of Insurance Control Over Health Bill Outcome, Praises House Version, 'Disappointed' by Senate; Weiner and Policy Analyst Jordan Osserman Offer Bill's 'Prognosis' 2

Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures WebMD to Present at the Canaccord Adams 29th Annual Global Growth Conference Red Cross Poll Shows Parents Still Lack H1N1 Information From Schools U.S. Stem Cell Research Seems to Focus on Two Lines Fumbled handoffs can lead to medical errors Ex-House Aging Committee Chief of Staff Bob Weiner Warns of Insurance Control Over Health Bill Outcome, Praises House Version, 'Disappointed' by Senate; Weiner and Policy Analyst Jordan Osserman Offer Bill's 'Prognosis'

Malaria Pf. Assay Range...

An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood....

192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....

Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...

Medicine Products:

Malaria Pf. Assay Range PALUTOP+4 Malaria Antigen CELISA Malaria Device / Strip (3 line, PAN-pLDH, P.f.-HRP2)